Nurix Therapeutics Earnings
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
22.35+0.14 (+0.63%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nurix Therapeutics earnings summary
In its most recent report on Jul 9, 2026 (Q2 2026), NRIX posted EPS of $-0.81. Revenue for the quarter was $9.0 million. Across the last 16 reports, NRIX shares moved an average of 8.5% (in either direction) in the first trading session after results, rising 8 times and falling 8 times.
Summary generated from market data by MetaCap's automated system. Methodology
NRIX earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Jul 9, 2026 | — | $-0.81 | — | +0.3% |
| Apr 8, 2026 | — | $-0.79 | — | +9.2% |
| Jan 28, 2026 | — | $-0.83 | — | +2.0% |
| Oct 9, 2025 | — | $-1.03 | — | +0.8% |
| Jul 9, 2025 | — | $-0.52 | — | -9.9% |
| Apr 8, 2025 | — | $-0.67 | — | +12.0% |
| Jan 28, 2025 | — | $-0.74 | — | -4.2% |
| Oct 11, 2024 | — | $-0.67 | — | +6.0% |
| Jul 11, 2024 | — | $-0.71 | — | -12.8% |
| Apr 10, 2024 | — | $-0.76 | — | -18.8% |
| Feb 15, 2024 | — | $-0.77 | — | +3.3% |
| Oct 12, 2023 | — | $-0.68 | — | -25.0% |
| Jul 13, 2023 | — | $-0.45 | — | +3.2% |
| Apr 13, 2023 | — | $-0.75 | — | -11.6% |
| Feb 9, 2023 | — | $-0.85 | — | -16.6% |
| Oct 6, 2022 | — | $-0.90 | — | -0.9% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.